Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database

The efficacy and safety of statins have been studied in a number of clinical trials and epidemiological studies. In recent years, the Medicine and Healthcare Products Regulatory Agency (MHRA) has assessed the evidence available on the following adverse reactions associated with the use of statins: s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical pharmacology and therapeutics 2014-09, Vol.52 (9), p.762-769
Hauptverfasser: FUJIMOTO, Mai, HIGUCHI, Tomoya, HOSOMI, Kouichi, TAKADA, Mitsutaka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 769
container_issue 9
container_start_page 762
container_title International journal of clinical pharmacology and therapeutics
container_volume 52
creator FUJIMOTO, Mai
HIGUCHI, Tomoya
HOSOMI, Kouichi
TAKADA, Mitsutaka
description The efficacy and safety of statins have been studied in a number of clinical trials and epidemiological studies. In recent years, the Medicine and Healthcare Products Regulatory Agency (MHRA) has assessed the evidence available on the following adverse reactions associated with the use of statins: sleep disturbances, memory loss, micturition disorders (problems with urination), sexual disturbances, depression, and interstitial pneumopathy. However, the association between statin use and the risk of these adverse reactions remains unclear. To examine the association between statin use and the risk of lower urinary tract symptoms (LUTS) or the disorder causing LUTS, we carried out data mining using a prescription database. A large organized database of prescriptions constructed by a database vendor was used in the study. Symmetry analysis was used to identify the risk of LUTS after using statins over the period January 2006 to August 2013. Statin use in combination with drugs administered for storage LUTS was examined by prescription sequence symmetry analysis (PSSA). A significant association between statins and drugs for storage LUTS was found, with adjusted sequence ratios (ASRs) of 1.21 (95% CI, 1.00 - 1.46), 1.19 (95% CI, 1.04 - 1.38), and 1.17 (95% CI, 1.05 - 1.30) for intervals of 91, 182, and 365 days, respectively. In the analyses of individual statins, significant associations were found only for pravastatin. Significant associations with individual drugs for storage LUTS were found for solifenacin succinate with ASRs of 1.36 (95% CI, 1.02 - 1.81), 1.48 (95% CI, 1.19 - 1.84), and 1.47 (95% CI, 1.25 - 1.73) for intervals of 91, 182, and 365 days, for flavoxate hydrochloride with an ASR of 1.56 (95% CI, 1.13 - 2.17) at an interval of 182 days, and for oxybutynin hydrochloride with ASRs of 2.06 (95% CI, 1.11 - 3.94) and 1.71 (95% CI, 1.09 - 2.72) at intervals of 182 and 365 days. Significant associations with gender were found only in females with ASRs of 1.25 (95% CI, 1.04 - 1.51) and 1.23 (95% CI, 1.07 - 1.41) at intervals of 182 and 365 days, respectively. Analysis of the prescription database showed significant association for storage LUTS in statin users.
doi_str_mv 10.5414/CP202113
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1552808338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1552808338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c313t-7945b876200d0fe256ca1dcddd3a3526d9311e6c6b9cc4520215bb49544287a83</originalsourceid><addsrcrecordid>eNpNkMtKxDAUhrNQvIyCTyDZCONiNPc27obBGwwoqOuSpukYaZuakzL49nZ0vKzOOZyPD_4foRNKLqSg4nLxyAijlO-gA6KFmlGt5D46BHgjhEmZ6T20z4TOFdHyAPVzgGC9ST50ONQY0rh2eACH1z69jneIZuVwE9Yu4iH6zsQPnKKxCcNH26fQAp4uX56fzq9wZZLBre98t9q4-ujARt9_uTe_0oA7Qru1acAdb-cEvdxcPy_uZsuH2_vFfDmznPI0y7SQZZ4pRkhFaseksoZWtqoqbrhkqtKcUqesKrW1Qm4iy7IUWgrB8szkfIKm394-hvfBQSpaD9Y1jelcGKCgUrKc5Jz_Q20MANHVRR99O-YsKCk2nRY_nY7o6dY6lK2rfsGfQkfgbAsYsKapo-mshz8uz0QmFeGfAmOALw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552808338</pqid></control><display><type>article</type><title>Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>FUJIMOTO, Mai ; HIGUCHI, Tomoya ; HOSOMI, Kouichi ; TAKADA, Mitsutaka</creator><creatorcontrib>FUJIMOTO, Mai ; HIGUCHI, Tomoya ; HOSOMI, Kouichi ; TAKADA, Mitsutaka</creatorcontrib><description>The efficacy and safety of statins have been studied in a number of clinical trials and epidemiological studies. In recent years, the Medicine and Healthcare Products Regulatory Agency (MHRA) has assessed the evidence available on the following adverse reactions associated with the use of statins: sleep disturbances, memory loss, micturition disorders (problems with urination), sexual disturbances, depression, and interstitial pneumopathy. However, the association between statin use and the risk of these adverse reactions remains unclear. To examine the association between statin use and the risk of lower urinary tract symptoms (LUTS) or the disorder causing LUTS, we carried out data mining using a prescription database. A large organized database of prescriptions constructed by a database vendor was used in the study. Symmetry analysis was used to identify the risk of LUTS after using statins over the period January 2006 to August 2013. Statin use in combination with drugs administered for storage LUTS was examined by prescription sequence symmetry analysis (PSSA). A significant association between statins and drugs for storage LUTS was found, with adjusted sequence ratios (ASRs) of 1.21 (95% CI, 1.00 - 1.46), 1.19 (95% CI, 1.04 - 1.38), and 1.17 (95% CI, 1.05 - 1.30) for intervals of 91, 182, and 365 days, respectively. In the analyses of individual statins, significant associations were found only for pravastatin. Significant associations with individual drugs for storage LUTS were found for solifenacin succinate with ASRs of 1.36 (95% CI, 1.02 - 1.81), 1.48 (95% CI, 1.19 - 1.84), and 1.47 (95% CI, 1.25 - 1.73) for intervals of 91, 182, and 365 days, for flavoxate hydrochloride with an ASR of 1.56 (95% CI, 1.13 - 2.17) at an interval of 182 days, and for oxybutynin hydrochloride with ASRs of 2.06 (95% CI, 1.11 - 3.94) and 1.71 (95% CI, 1.09 - 2.72) at intervals of 182 and 365 days. Significant associations with gender were found only in females with ASRs of 1.25 (95% CI, 1.04 - 1.51) and 1.23 (95% CI, 1.07 - 1.41) at intervals of 182 and 365 days, respectively. Analysis of the prescription database showed significant association for storage LUTS in statin users.</description><identifier>ISSN: 0946-1965</identifier><identifier>DOI: 10.5414/CP202113</identifier><identifier>PMID: 24986095</identifier><language>eng</language><publisher>München: Dustri</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Data Mining ; Databases, Pharmaceutical ; Drug Prescriptions ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Japan ; Lower Urinary Tract Symptoms - chemically induced ; Lower Urinary Tract Symptoms - diagnosis ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Pharmacology. Drug treatments ; Risk Assessment ; Risk Factors ; Time Factors ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland ; Young Adult</subject><ispartof>International journal of clinical pharmacology and therapeutics, 2014-09, Vol.52 (9), p.762-769</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c313t-7945b876200d0fe256ca1dcddd3a3526d9311e6c6b9cc4520215bb49544287a83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28747560$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24986095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FUJIMOTO, Mai</creatorcontrib><creatorcontrib>HIGUCHI, Tomoya</creatorcontrib><creatorcontrib>HOSOMI, Kouichi</creatorcontrib><creatorcontrib>TAKADA, Mitsutaka</creatorcontrib><title>Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database</title><title>International journal of clinical pharmacology and therapeutics</title><addtitle>Int J Clin Pharmacol Ther</addtitle><description>The efficacy and safety of statins have been studied in a number of clinical trials and epidemiological studies. In recent years, the Medicine and Healthcare Products Regulatory Agency (MHRA) has assessed the evidence available on the following adverse reactions associated with the use of statins: sleep disturbances, memory loss, micturition disorders (problems with urination), sexual disturbances, depression, and interstitial pneumopathy. However, the association between statin use and the risk of these adverse reactions remains unclear. To examine the association between statin use and the risk of lower urinary tract symptoms (LUTS) or the disorder causing LUTS, we carried out data mining using a prescription database. A large organized database of prescriptions constructed by a database vendor was used in the study. Symmetry analysis was used to identify the risk of LUTS after using statins over the period January 2006 to August 2013. Statin use in combination with drugs administered for storage LUTS was examined by prescription sequence symmetry analysis (PSSA). A significant association between statins and drugs for storage LUTS was found, with adjusted sequence ratios (ASRs) of 1.21 (95% CI, 1.00 - 1.46), 1.19 (95% CI, 1.04 - 1.38), and 1.17 (95% CI, 1.05 - 1.30) for intervals of 91, 182, and 365 days, respectively. In the analyses of individual statins, significant associations were found only for pravastatin. Significant associations with individual drugs for storage LUTS were found for solifenacin succinate with ASRs of 1.36 (95% CI, 1.02 - 1.81), 1.48 (95% CI, 1.19 - 1.84), and 1.47 (95% CI, 1.25 - 1.73) for intervals of 91, 182, and 365 days, for flavoxate hydrochloride with an ASR of 1.56 (95% CI, 1.13 - 2.17) at an interval of 182 days, and for oxybutynin hydrochloride with ASRs of 2.06 (95% CI, 1.11 - 3.94) and 1.71 (95% CI, 1.09 - 2.72) at intervals of 182 and 365 days. Significant associations with gender were found only in females with ASRs of 1.25 (95% CI, 1.04 - 1.51) and 1.23 (95% CI, 1.07 - 1.41) at intervals of 182 and 365 days, respectively. Analysis of the prescription database showed significant association for storage LUTS in statin users.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Data Mining</subject><subject>Databases, Pharmaceutical</subject><subject>Drug Prescriptions</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Japan</subject><subject>Lower Urinary Tract Symptoms - chemically induced</subject><subject>Lower Urinary Tract Symptoms - diagnosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Urinary tract. Prostate gland</subject><subject>Young Adult</subject><issn>0946-1965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMtKxDAUhrNQvIyCTyDZCONiNPc27obBGwwoqOuSpukYaZuakzL49nZ0vKzOOZyPD_4foRNKLqSg4nLxyAijlO-gA6KFmlGt5D46BHgjhEmZ6T20z4TOFdHyAPVzgGC9ST50ONQY0rh2eACH1z69jneIZuVwE9Yu4iH6zsQPnKKxCcNH26fQAp4uX56fzq9wZZLBre98t9q4-ujARt9_uTe_0oA7Qru1acAdb-cEvdxcPy_uZsuH2_vFfDmznPI0y7SQZZ4pRkhFaseksoZWtqoqbrhkqtKcUqesKrW1Qm4iy7IUWgrB8szkfIKm394-hvfBQSpaD9Y1jelcGKCgUrKc5Jz_Q20MANHVRR99O-YsKCk2nRY_nY7o6dY6lK2rfsGfQkfgbAsYsKapo-mshz8uz0QmFeGfAmOALw</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>FUJIMOTO, Mai</creator><creator>HIGUCHI, Tomoya</creator><creator>HOSOMI, Kouichi</creator><creator>TAKADA, Mitsutaka</creator><general>Dustri</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database</title><author>FUJIMOTO, Mai ; HIGUCHI, Tomoya ; HOSOMI, Kouichi ; TAKADA, Mitsutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c313t-7945b876200d0fe256ca1dcddd3a3526d9311e6c6b9cc4520215bb49544287a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Data Mining</topic><topic>Databases, Pharmaceutical</topic><topic>Drug Prescriptions</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Japan</topic><topic>Lower Urinary Tract Symptoms - chemically induced</topic><topic>Lower Urinary Tract Symptoms - diagnosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Urinary tract. Prostate gland</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FUJIMOTO, Mai</creatorcontrib><creatorcontrib>HIGUCHI, Tomoya</creatorcontrib><creatorcontrib>HOSOMI, Kouichi</creatorcontrib><creatorcontrib>TAKADA, Mitsutaka</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FUJIMOTO, Mai</au><au>HIGUCHI, Tomoya</au><au>HOSOMI, Kouichi</au><au>TAKADA, Mitsutaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database</atitle><jtitle>International journal of clinical pharmacology and therapeutics</jtitle><addtitle>Int J Clin Pharmacol Ther</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>52</volume><issue>9</issue><spage>762</spage><epage>769</epage><pages>762-769</pages><issn>0946-1965</issn><abstract>The efficacy and safety of statins have been studied in a number of clinical trials and epidemiological studies. In recent years, the Medicine and Healthcare Products Regulatory Agency (MHRA) has assessed the evidence available on the following adverse reactions associated with the use of statins: sleep disturbances, memory loss, micturition disorders (problems with urination), sexual disturbances, depression, and interstitial pneumopathy. However, the association between statin use and the risk of these adverse reactions remains unclear. To examine the association between statin use and the risk of lower urinary tract symptoms (LUTS) or the disorder causing LUTS, we carried out data mining using a prescription database. A large organized database of prescriptions constructed by a database vendor was used in the study. Symmetry analysis was used to identify the risk of LUTS after using statins over the period January 2006 to August 2013. Statin use in combination with drugs administered for storage LUTS was examined by prescription sequence symmetry analysis (PSSA). A significant association between statins and drugs for storage LUTS was found, with adjusted sequence ratios (ASRs) of 1.21 (95% CI, 1.00 - 1.46), 1.19 (95% CI, 1.04 - 1.38), and 1.17 (95% CI, 1.05 - 1.30) for intervals of 91, 182, and 365 days, respectively. In the analyses of individual statins, significant associations were found only for pravastatin. Significant associations with individual drugs for storage LUTS were found for solifenacin succinate with ASRs of 1.36 (95% CI, 1.02 - 1.81), 1.48 (95% CI, 1.19 - 1.84), and 1.47 (95% CI, 1.25 - 1.73) for intervals of 91, 182, and 365 days, for flavoxate hydrochloride with an ASR of 1.56 (95% CI, 1.13 - 2.17) at an interval of 182 days, and for oxybutynin hydrochloride with ASRs of 2.06 (95% CI, 1.11 - 3.94) and 1.71 (95% CI, 1.09 - 2.72) at intervals of 182 and 365 days. Significant associations with gender were found only in females with ASRs of 1.25 (95% CI, 1.04 - 1.51) and 1.23 (95% CI, 1.07 - 1.41) at intervals of 182 and 365 days, respectively. Analysis of the prescription database showed significant association for storage LUTS in statin users.</abstract><cop>München</cop><pub>Dustri</pub><pmid>24986095</pmid><doi>10.5414/CP202113</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0946-1965
ispartof International journal of clinical pharmacology and therapeutics, 2014-09, Vol.52 (9), p.762-769
issn 0946-1965
language eng
recordid cdi_proquest_miscellaneous_1552808338
source MEDLINE; Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Biological and medical sciences
Data Mining
Databases, Pharmaceutical
Drug Prescriptions
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Japan
Lower Urinary Tract Symptoms - chemically induced
Lower Urinary Tract Symptoms - diagnosis
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Pharmacology. Drug treatments
Risk Assessment
Risk Factors
Time Factors
Urinary system involvement in other diseases. Miscellaneous
Urinary tract. Prostate gland
Young Adult
title Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A51%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20statin%20use%20with%20storage%20lower%20urinary%20tract%20symptoms%20(LUTS):%20data%20mining%20of%20prescription%20database&rft.jtitle=International%20journal%20of%20clinical%20pharmacology%20and%20therapeutics&rft.au=FUJIMOTO,%20Mai&rft.date=2014-09-01&rft.volume=52&rft.issue=9&rft.spage=762&rft.epage=769&rft.pages=762-769&rft.issn=0946-1965&rft_id=info:doi/10.5414/CP202113&rft_dat=%3Cproquest_cross%3E1552808338%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552808338&rft_id=info:pmid/24986095&rfr_iscdi=true